
|Articles|June 10, 2019
Neuroprotective implant for treatment of glaucoma in phase II trial
Author(s)Julianne Mobilian
Here's the latest innovations at Neurotech Pharmaceuticals, Inc.
Advertisement
Rich Small, CPA, CEO of
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Neurotrophic keratitis outcomes improve with early, stage-based care
5














































.png)


